KRAS and cholangiocarcinoma: Interestingly, the two targets of miR-877 reported in Table S2 included K-RAS, which plays a major role in both CCA and PDAC carcinogenesis (though K-RAS mutations are present in 90% of early stage PDACs, 61% of the ampullary cancers, but only in 15.2% of bile duct cancers [37]).